Diabetes, Vol 48, Issue 3 649-651, Copyright © 1999 by American Diabetes Association

ARTICLES

Mice transgenic for an expanded CAG repeat in the Huntington's disease gene develop diabetes

MS Hurlbert, W Zhou, C Wasmeier, FG Kaddis, JC Hutton and CR Freed
Department of Medicine, University of Colorado Health Sciences Center, Denver, USA.

The autosomal dominant neurological syndrome of Huntington's disease has been modeled in transgenic mice by the expression of a portion of the human huntingtin gene together with 140 CAG repeats (the R6/2 strain). The mice develop progressive chorea with onset at approximately 9 weeks of age and with death at approximately 13 weeks. Associated symptoms include weight loss and polyuria in the absence of eating or drinking deficits. We have found that these mice have insulin-responsive diabetes. Fasting glucose was 211 + 19 mg/dl in R6/2 mice compared with 93 + 5 mg/dl in C57/B6 controls (n = 12, both groups; P < 0.01). Administration of insulin intraperitoneally led to a reduction in blood glucose. At 12.5 weeks, animals were killed and pancreas weighed and analyzed for insulin and glucagon. Pancreatic mass in R6/2 mice was the same as controls, and islets appeared normal in morphology without lymphocytic infiltration. Immunohistochemical staining showed dramatic reductions in glucagon in the alpha-cells and in insulin in the beta-cells. Direct tissue assays showed glucagon and insulin content were reduced to only 10 and 15% of controls, respectively. Diabetes has been reported as being more common in Huntington's disease and other triplet repeat disorders. The R6/2 mouse should prove useful for elucidating the mechanism of diabetes in these genetic diseases.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				N. M. Lalic, J. Maric, M. Svetel, A. Jotic, E. Stefanova, K. Lalic, N. Dragasevic, T. Milicic, L. Lukic, and V. S. Kostic Glucose Homeostasis in Huntington Disease: Abnormalities in Insulin Sensitivity and Early-Phase Insulin Secretion Arch Neurol, April 1, 2008; 65(4): 476 - 480. [Abstract] [Full Text] [PDF]

				M. Y. Heng, S. J. Tallaksen-Greene, P. J. Detloff, and R. L. Albin Longitudinal Evaluation of the Hdh(CAG)150 Knock-In Murine Model of Huntington's Disease J. Neurosci., August 22, 2007; 27(34): 8989 - 8998. [Abstract] [Full Text] [PDF]

				U. Bichelmeier, T. Schmidt, J. Hubener, J. Boy, L. Ruttiger, K. Habig, S. Poths, M. Bonin, M. Knipper, W. J. Schmidt, et al. Nuclear Localization of Ataxin-3 Is Required for the Manifestation of Symptoms in SCA3: In Vivo Evidence J. Neurosci., July 11, 2007; 27(28): 7418 - 7428. [Abstract] [Full Text] [PDF]

				A. Fergani, H. Oudart, J.-L. Gonzalez De Aguilar, B. Fricker, F. Rene, J.-F. Hocquette, V. Meininger, L. Dupuis, and J.-P. Loeffler Increased peripheral lipid clearance in an animal model of amyotrophic lateral sclerosis J. Lipid Res., July 1, 2007; 48(7): 1571 - 1580. [Abstract] [Full Text] [PDF]

				M.-C. Chiang, H.-M. Chen, Y.-H. Lee, H.-H. Chang, Y.-C. Wu, B.-W. Soong, C.-M. Chen, Y.-R. Wu, C.-S. Liu, D.-M. Niu, et al. Dysregulation of C/EBP{alpha} by mutant Huntingtin causes the urea cycle deficiency in Huntington's disease Hum. Mol. Genet., March 1, 2007; 16(5): 483 - 498. [Abstract] [Full Text] [PDF]

				A. D. Steele, W. S. Jackson, O. D. King, and S. Lindquist The power of automated high-resolution behavior analysis revealed by its application to mouse models of Huntington's and prion diseases PNAS, February 6, 2007; 104(6): 1983 - 1988. [Abstract] [Full Text] [PDF]

				M. Bjorkqvist, A. Petersen, K. Bacos, J. Isaacs, P. Norlen, J. Gil, N. Popovic, F. Sundler, G. P. Bates, S. J. Tabrizi, et al. Progressive alterations in the hypothalamic-pituitary-adrenal axis in the R6/2 transgenic mouse model of Huntington's disease Hum. Mol. Genet., May 15, 2006; 15(10): 1713 - 1721. [Abstract] [Full Text] [PDF]

				J. M. Van Raamsdonk, W. T. Gibson, J. Pearson, Z. Murphy, G. Lu, B. R. Leavitt, and M. R. Hayden Body weight is modulated by levels of full-length Huntingtin Hum. Mol. Genet., May 1, 2006; 15(9): 1513 - 1523. [Abstract] [Full Text] [PDF]

				M. Fujimoto, E. Takaki, T. Hayashi, Y. Kitaura, Y. Tanaka, S. Inouye, and A. Nakai Active HSF1 Significantly Suppresses Polyglutamine Aggregate Formation in Cellular and Mouse Models J. Biol. Chem., October 14, 2005; 280(41): 34908 - 34916. [Abstract] [Full Text] [PDF]

				T. Nguyen, A. Hamby, and S. M. Massa Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model PNAS, August 16, 2005; 102(33): 11840 - 11845. [Abstract] [Full Text] [PDF]

				A. D. Strand, A. K. Aragaki, D. Shaw, T. Bird, J. Holton, C. Turner, S. J. Tapscott, S. J. Tabrizi, A. H. Schapira, C. Kooperberg, et al. Gene expression in Huntington's disease skeletal muscle: a potential biomarker Hum. Mol. Genet., July 1, 2005; 14(13): 1863 - 1876. [Abstract] [Full Text] [PDF]

				M. Bjorkqvist, M. Fex, E. Renstrom, N. Wierup, A. Petersen, J. Gil, K. Bacos, N. Popovic, J.-Y. Li, F. Sundler, et al. The R6/2 transgenic mouse model of Huntington's disease develops diabetes due to deficient {beta}-cell mass and exocytosis Hum. Mol. Genet., March 1, 2005; 14(5): 565 - 574. [Abstract] [Full Text] [PDF]

				G. J. Klapstein and M. S. Levine Age-Dependent Biphasic Changes in Ischemic Sensitivity in the Striatum of Huntington's Disease R6/2 Transgenic Mice J Neurophysiol, February 1, 2005; 93(2): 758 - 765. [Abstract] [Full Text] [PDF]

				M. J. Calkins, R. J. Jakel, D. A. Johnson, K. Chan, Y. W. Kan, and J. A. Johnson Protection from mitochondrial complex II inhibition in vitro and in vivo by Nrf2-mediated transcription PNAS, January 4, 2005; 102(1): 244 - 249. [Abstract] [Full Text] [PDF]

				E. Regulier, Y. Trottier, V. Perrin, P. Aebischer, and N. Deglon Early and reversible neuropathology induced by tetracycline-regulated lentiviral overexpression of mutant huntingtin in rat striatum Hum. Mol. Genet., November 1, 2003; 12(21): 2827 - 2836. [Abstract] [Full Text] [PDF]

				S. Holbert, A. Dedeoglu, S. Humbert, F. Saudou, R. J. Ferrante, and C. Neri Cdc42-interacting protein 4 binds to huntingtin: Neuropathologic and biological evidence for a role in Huntington's disease PNAS, March 4, 2003; 100(5): 2712 - 2717. [Abstract] [Full Text] [PDF]

				W. Duan, Z. Guo, H. Jiang, M. Ware, X.-J. Li, and M. P. Mattson Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice PNAS, March 4, 2003; 100(5): 2911 - 2916. [Abstract] [Full Text] [PDF]

				D. Helmlinger, G. Yvert, S. Picaud, K. Merienne, J. Sahel, J.-L. Mandel, and D. Devys Progressive retinal degeneration and dysfunction in R6 Huntington's disease mice Hum. Mol. Genet., December 15, 2002; 11(26): 3351 - 3359. [Abstract] [Full Text] [PDF]

				R. Luthi-Carter, S. A. Hanson, A. D. Strand, D. A. Bergstrom, W. Chun, N. L. Peters, A. M. Woods, E. Y. Chan, C. Kooperberg, D. Krainc, et al. Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain Hum. Mol. Genet., August 15, 2002; 11(17): 1911 - 1926. [Abstract] [Full Text] [PDF]

				L. P. de Almeida, C. A. Ross, D. Zala, P. Aebischer, and N. Deglon Lentiviral-Mediated Delivery of Mutant Huntingtin in the Striatum of Rats Induces a Selective Neuropathology Modulated by Polyglutamine Repeat Size, Huntingtin Expression Levels, and Protein Length J. Neurosci., May 1, 2002; 22(9): 3473 - 3483. [Abstract] [Full Text] [PDF]

				H. Adachi, A. Kume, M. Li, Y. Nakagomi, H. Niwa, J. Do, C. Sang, Y. Kobayashi, M. Doyu, and G. Sobue Transgenic mice with an expanded CAG repeat controlled by the human AR promoter show polyglutamine nuclear inclusions and neuronal dysfunction without neuronal cell death Hum. Mol. Genet., May 1, 2001; 10(10): 1039 - 1048. [Abstract] [Full Text] [PDF]

				C.-H. Lin, S. Tallaksen-Greene, W.-M. Chien, J. A. Cearley, W. S. Jackson, A. B. Crouse, S. Ren, X.-J. Li, R. L. Albin, and P. J. Detloff Neurological abnormalities in a knock-in mouse model of Huntington's disease Hum. Mol. Genet., January 1, 2001; 10(2): 137 - 144. [Abstract] [Full Text] [PDF]

				K. P. S. J. Murphy, R. J. Carter, L. A. Lione, L. Mangiarini, A. Mahal, G. P. Bates, S. B. Dunnett, and A. J. Morton Abnormal Synaptic Plasticity and Impaired Spatial Cognition in Mice Transgenic for Exon 1 of the Human Huntington's Disease Mutation J. Neurosci., July 1, 2000; 20(13): 5115 - 5123. [Abstract] [Full Text] [PDF]

				R. J. Ferrante, O. A. Andreassen, B. G. Jenkins, A. Dedeoglu, S. Kuemmerle, J. K. Kubilus, R. Kaddurah-Daouk, S. M. Hersch, and M. F. Beal Neuroprotective Effects of Creatine in a Transgenic Mouse Model of Huntington's Disease J. Neurosci., June 15, 2000; 20(12): 4389 - 4397. [Abstract] [Full Text] [PDF]

				R. Luthi-Carter, A. Strand, N. L. Peters, S. M. Solano, Z. R. Hollingsworth, A. S. Menon, A. S. Frey, B. S. Spektor, E. B. Penney, G. Schilling, et al. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease Hum. Mol. Genet., May 22, 2000; 9(9): 1259 - 1271. [Abstract] [Full Text] [PDF]

				V. C. Wheeler, J. K. White, C.-A. Gutekunst, V. Vrbanac, M. Weaver, X.-J. Li, S.-H. Li, H. Yi, J.-P. Vonsattel, J. F. Gusella, et al. Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice Hum. Mol. Genet., March 1, 2000; 9(4): 503 - 513. [Abstract] [Full Text] [PDF]

				L. A. Lione, R. J. Carter, M. J. Hunt, G. P. Bates, A. J. Morton, and S. B. Dunnett Selective Discrimination Learning Impairments in Mice Expressing the Human Huntington's Disease Mutation J. Neurosci., December 1, 1999; 19(23): 10428 - 10437. [Abstract] [Full Text] [PDF]

				O. Hansson, A. Petersen, M. Leist, P. Nicotera, R. F. Castilho, and P. Brundin Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity PNAS, July 20, 1999; 96(15): 8727 - 8732. [Abstract] [Full Text] [PDF]

				J. Carmichael, J. Chatellier, A. Woolfson, C. Milstein, A. R. Fersht, and D. C. Rubinsztein Bacterial and yeast chaperones reduce both aggregate formation and cell death in mammalian cell models of Huntington's disease PNAS, August 15, 2000; 97(17): 9701 - 9705. [Abstract] [Full Text] [PDF]